参考文献/References:
[1] Riccabona G,Decristoforo C.Peptide targeted imaging of cancer.Cancer Biother Radiopharm,2003,18(5):675-687.
[2] Said Si,Mutt V.Polypeptide with broad biological activity:isolation from small intestine.Science,1970,169(951):1217-1218.
[3] Onoue S,Matsumoto A,Nagano Y,et al.Alpha-helical structure in the C-terminus of vasoactive intestinal peptide:functional and structural consequences.Eur J Pharmacol,2004,485(1-3):307-316.
[4] Hoare SR.Mechanisms of peptide and non-peptide ligand binding to Class B G-protein-coupled receptors.Drug Discov Today,2005,10(6):417-427.
[5] Laburthe M,Couvineau A,Marie JC.VPAC receptors for VIP and PACAP.Receptors Channels,2002,8(3-4):137-153.
[6] Laburthe M,Couvineau A.Molecular pharmacology and structure of VPAC Receptor for VIP and PACAP.Regul Pept,2002,108(2-3):165-173.
[7] Bokaei PB,Ma XZ,Byczynski B,et al.Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors.Genomics,2006,88(6):791-800.
[8] Reubi JC.In vitro identification of vasoactive intestinal peptide receptors in human tumors:implications for tumor imaging.J Nucl Med,1995,36(10):1846-1853.
[9] Reubi JC,Läderach U,Waser B,et al.Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.Cancer Res,2000,60(11):3105-3112.
[10] Moody TW,Jensen RT.Breast cancer VPAC1 receptors.Ann N Y Acad Sci,2006,1070:436-439.
[11] Virgolini I,Yang Q,Li S,et al.Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.Cancer Res,1994,54(3):690-700.
[12] Koch TR,Michener SR,Go VL. Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea.Gastroenterology,1991,100(1):99-106.
[13] Hejna M,Hamilton G,Brodowicz T,et al.Serum levels of vasoactive intestinal peptide(VIP) in patients with adenocarcinomas of the gastrointestinal tract.Anticancer Res,2001,21(2A):1183-1187.
[14] Collado B,Carmena MJ,Clemente C,et al.Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model.Peptides,2007,28(9):1896-1901.
[15] Valdehita A,Carmena MJ,Collado B,et al. Vasoactive intestinal peptide(VIP) increases vascular endothelial growth factor(VEGF) expression and secretion in human breast cancer cells.Regul Pept,2007,144(1-3):101-108.
[16] Valdehita A,Bajo AM,Fernández-Martínez AB,et al.Nuclear localization of vasoactive intestinal peptide(VIP) receptors in human breast cancer.Peptides,2010,31(11):2035-2045.
[17] Virgolini I,Raderer M,Kurtaran A,et al.Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.N Engl J Med,1994,331(17):1116-1121.
[18] Raderer M,Kurtaran A,Hejna M,et al.123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.Br J Cancer,1998,78(1):1-5.
[19] Raderer M,Kurtaran A,Yang Q,et al.Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.J Nucl Med,1998,39(9):1570-1575.
[20] Pallela VR,Thakur ML,Chakder S,et al.99mTc-labeled vasoactive intestinal peptide receptor agonist:functional studies.J Nucl Med,1999,40(2):352-360.
[21] Rao PS,Thakur ML,Pallela V,et al.99mTc labeled VIP analog:evaluation for imaging colorectal cancer.Nucl Med Biol,2001,28(4):445-450.
[22] Virgolini I,Traub T,Oflucoglu S,et al.Human biodistribution,safety and absorbed dose of 99mTc-P1666 vasoactive intestinal peptide(VIP) receptor scintigraphy.J Nucl Med,1999,40:244(abstract)
[23] Thakur ML,Marcus CS,Saeed S,et al.Imaging tumors in humans with Tc-99m-VIP.Ann N Y Acad Sci,2000,921:37-44.
[24] Kothari K,Prasad S,Korde A,et al.99mTc(CO)3-VIP analogues:preparation and evaluation as tumor imaging agent.Appl Radiat Isot,2007,65(4):382-386.
[25] Moody TW,Leyton J,Unsworth E,et al.Arg15,Arg21) VIP:evaluation of biological activity and localization to breast cancer tumors.Peptides,1998,19(3):585-592.
[26] Cheng DF,Yin DZ,Zhang L,et al.Preparation of the novel fluorine-18-labeled VIP analog for PET imaging studies using two different synthesis methods.J Fluorine Chem,2007,128(3):196-201.
[27] Zhang K,Aruva MR,Shanthly N,et al.Vasoactive intestinal peptide(VIP) and pituitary adenylate cyclase activating peptide(PACAP) receptor specific peptide analogues for PET imaging of breast cancer:In vitro/in vivo evaluation.Regul Pept,2007,144(1-3):91-100.
[28] Zhang K,Aruva MR,Shanthly N,et al.PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.J Nucl Med,2008,49(1):112-121.
[29] Moody TW,Zia F,Draoui M,et al.A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.Proc Natl Acad Sci USA,1993,90(10):4345-4349.
[30] Moody TW,Jensen RT,Fridkin M,et al.(N-stearyl,norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.J Mol Neurosci,2002,18(1-2):29-35.
[31] Moody TW,Czerwinski Gt Tarasova NI,et al.VIP-ellipticine derivatives inhibit the growth of breast cancer cells.Life Sci,2002,71(9):1005-1014.
[32] Moody TW,Czerwinski G,Tarasova NI,et al.The development of VIP-ellipticine conjugates.Regul Pept,2004,123(1-3):187-192.
[33] Moody TW,Mantey SA,Fuselier JA,et al.Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.Peptides,2007,28(9):1883-1890.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]